At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Cariprazine 3 mg +2 moredrug
Likely dose
Cariprazine 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of MP-214 in Patients With Schizophrenia (Exploratory Study)
In Brief
A Phase 2 clinical trial evaluating Cariprazine 3 mg, Cariprazine 6 mg, and 1 other intervention for Schizophrenia. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be administered to patients starting at an initial dose, followed by up-titration to a fixed dose (low, medium or high) for 14 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMar 2009
Primary CompletionSep 2009
TodayJul 2026
First PostedMar 17, 2009
Enrollment StartApr 1, 2008
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.3 years ago
Interventions
Cariprazine 3 mgdrug
Cariprazine 6 mgdrug
Cariprazine 12.5 mgdrug